NEW YORK (GenomeWeb) – Myriad RBM announced today that it has signed an agreement to help Sanofi measure cardiovascular risk biomarkers in the blood samples of patients in a Phase III trial of its type II diabetes therapy lixisenatide.
...and receive Daily News bulletins.
Already have a GenomeWeb or 360Dx account?Login Now.
Don't have a GenomeWeb or 360Dx account?Register for Free.
The New York Times reports on an effort to address in high school biology classes misconceptions regarding race and genetics.
60 Minutes speaks with Harvard's George Church about tackling the effects of aging and more.
In PLOS this week: rare alterations in Timothy syndrome, analysis of twins' gut microbiomes, and more.
GenomeWeb reports that Veritas Genetics is suspending its US operations.